Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non Small Cell Lung Cancer
Both
Non Small Cell Lung Cancer
Trial Information
Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Inclusion Criteria:
- Histological or cytological confirmation of locally advanced or metastatic Non Small
Cell Lung Cancer (IIIB-IV)
- Tumour sample (block of slides) available for KRAS analysis
Exclusion Criteria:
- Confirmation of locally advanced or metastatic NSCLC (IIIB-IV) exclusively by
cytology, with no tumour sample access.
- Previous treatment using a MEK inhibitor or any other regimen containing docetaxel
(previous treatment with paclitaxel is accepted)
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
To analyze the frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC.
Outcome Time Frame:
March 31, 2010
Safety Issue:
No
Principal Investigator
José Eduardo Pipolo das Neves, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca do Brasil, MC Medical Director
Authority:
Brazil: Ethics Committee
Study ID:
NIS-OBR-DUM-2008/1
NCT ID:
NCT00956280
Start Date:
September 2009
Completion Date:
April 2010
Related Keywords:
- Non Small Cell Lung Cancer
- The frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC
- KRAS mutation in population with advanced NSCLC
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
